Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
Rashed Noor, Saadia Shareen, A. H. M. Muntasir Billah
Bulletin of the National Research Centre/Bulletin of the National Research Center (2022) Vol. 46, Iss. 1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

COVID-19 Vaccines: An Updated Overview of Different Platforms
D.А. Кudlay, Andrey Svistunov, Олег Викторович Сатышев
Bioengineering (2022) Vol. 9, Iss. 11, pp. 714-714
Open Access | Times Cited: 19
What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions
Toru Awaya, Masao Moroi, Yoshinari Enomoto, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 866-866
Open Access | Times Cited: 17
SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes
Fadi Aljamaan, Mohamad‐Hani Temsah, Khalid Alhasan, et al.
Journal of Infection and Public Health (2022) Vol. 15, Iss. 7, pp. 773-780
Open Access | Times Cited: 16
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Adaptation‐Proof SARS‐CoV‐2 Vaccine Design
Yashavantha L. Vishweshwaraiah, Brianna Hnath, Brendan Rackley, et al.
Advanced Functional Materials (2022) Vol. 32, Iss. 49
Open Access | Times Cited: 13
The Community Pharmacy as a Study Center for the Epidemiological Analysis of the Population Vaccination against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service
Jacopo Raffaele Dibenedetto, Michela Cetrone, Marina Antonacci, et al.
Pharmacy (2024) Vol. 12, Iss. 1, pp. 16-16
Open Access | Times Cited: 2
Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 8
Open Access | Times Cited: 11
Evaluating the in Vitro Efficacy of Quassinoids from Eurycoma longifolia and Eurycoma harmandiana against Common Cold Human Coronavirus OC43 and SARS-CoV-2 Using In-Cell Enzyme-Linked Immunosorbent Assay
Rattanathorn Choonong, Sasiporn Ruangdachsuwan, Theeraporn Churod, et al.
Journal of Natural Products (2022) Vol. 85, Iss. 12, pp. 2779-2788
Closed Access | Times Cited: 11
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 9, pp. 1253-1262
Open Access | Times Cited: 6
Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants
Sovan Samanta, Jhimli Banerjee, Aparna Das, et al.
Current Microbiology (2024) Vol. 81, Iss. 3
Closed Access | Times Cited: 1
Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants
Rashed Noor
Viruses (2022) Vol. 14, Iss. 11, pp. 2541-2541
Open Access | Times Cited: 7
Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
J. Shashidhar, Apoorva Munigela, Mitnala Sasikala, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2146-2146
Open Access | Times Cited: 7
Effect of a health education program about COVID-19 on the knowledge, attitude, and practices of paramedical students in Egypt: an interventional study
Osama Wassef, Souad Elgendy, Abd El-Moniem A. Younis Dawah, et al.
Journal of Public Health in Africa (2023) Vol. 14, Iss. 5, pp. 7-7
Open Access | Times Cited: 2
Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients
Yu Liu, Liunuobei Zhao, Li Wang, et al.
Heliyon (2023) Vol. 9, Iss. 7, pp. e18093-e18093
Open Access | Times Cited: 2
Novel sofosbuvir derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective
Abdulwahed Alrehaily, Abdo A. Elfiky, Ibrahim M. Ibrahim, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study
Qiao Guo, Lei Yang, Ran Peng, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 4
Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers
Sung Hee Lim, Han Jo Kim, Se Hyung Kim, et al.
Journal of Korean Medical Science (2023) Vol. 38, Iss. 13
Open Access | Times Cited: 2
Adaptation-proof SARS-CoV-2 vaccine design
Yashavantha L. Vishweshwaraiah, Brianna Hnath, Brendan Rackley, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Community Pharmacy as a Study Center for the Epidemio-logical Analysis of the Population Vaccination Against SARS-CoV-2: Regulatory Rules and Prescriptions
Jacopo Raffaele Dibenedetto, Michela Cetrone, Marina Antonacci, et al.
(2023)
Open Access | Times Cited: 1
Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2
Jun Wang, Liang Shao, Jing Liang, et al.
Journal of Cancer Research and Therapeutics (2023) Vol. 19, Iss. 6, pp. 1495-1500
Open Access | Times Cited: 1
Overview of dreadful consequences of SARS-CoV-2 invasion in Italy from March 2020 to March 2022
Asma Akter Bhuiyan, Sreyashi Brahmachari, Israt Jahan Ripa, et al.
Bulletin of the National Research Centre/Bulletin of the National Research Center (2022) Vol. 46, Iss. 1
Open Access | Times Cited: 2
How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?
Rashed Noor
Bulletin of the National Research Centre/Bulletin of the National Research Center (2022) Vol. 46, Iss. 1
Open Access | Times Cited: 2
Inflammatory reaction to recently applied red tattoo ink after COVID‐19
Uwe Wollina
Journal of Cosmetic Dermatology (2022) Vol. 21, Iss. 12, pp. 7237-7239
Open Access | Times Cited: 1
Patterns of protection, infection, and detection: Country-level effectiveness of COVID-19 vaccination in reducing mortality worldwide
Cosima Rughiniş, Mihai Dima, Simona–Nicoleta Vulpe, et al.
Public Health in Practice (2023) Vol. 6, pp. 100416-100416
Open Access
Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study
Sue Ann Costa Clemens, Eveline Pı́polo Milan, Eduardo Sprinz, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1 - Next Page

Scroll to top